Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

New CEOs named at Oxford, Angelini

Plus: Hegde becomes CSO at Congruence, and updates from Medivir and Grunenthal

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 
November 22, 2022 11:59 PM UTC

Gene and cell therapy company Oxford BioMedica plc (LSE:OXB) named Frank Mathias as CEO and board member, effective March 2023. Mathias served as CEO of Rentschler Biopharma SE, a CDMO, since 2016. Roch Doliveux, who is serving as interim CEO, will become non-executive chair.

Jacopo Andreose will become CEO at Angelini Pharma S.p.A. on Feb. 6, 2023. Andreose, a veteran of Abbott Laboratories (NYSE:ABT), was most recently SVP, intercontinental and global patient solutions at Gilead Sciences Inc. (NASDAQ:GILD). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Angelini Pharma S.p.A.

Congruence Therapeutics Inc.

Medivir AB

Oxford Biomedica plc